Patient characteristics
N | 41 |
| Median age, y (range) | 42 (19-62) |
| Sex, n, M/F | 26/15 |
| Stem cell source, n (%) | |
| Bone marrow | 41 (100) |
| Donor,* n (%) | |
| Histocompatible unrelated donor | 26 (68) |
| 5 of 6 unrelated donor | 8 (20) |
| 5 of 6 matched family member | 5 (12) |
| Diagnosis | |
| CML, n (%) | 12 (29) |
| Stable phase | 8 |
| Accelerated phase or second stable phase | 2 |
| Blast crisis | 2 |
| ALL, n (%) | 9 (22) |
| First remission | 4† |
| Second remission | 4 |
| Resistant relapse | 1 |
| AML, n (%) | 10 (24) |
| Second remission | 1 |
| Resistant relapse | 8 |
| Untreated relapse | 1 |
| Myelodysplasia, n (%) | 7 (17) |
| Non-Hodgkin lymphoma, n (%) | 2 (5) |
N | 41 |
| Median age, y (range) | 42 (19-62) |
| Sex, n, M/F | 26/15 |
| Stem cell source, n (%) | |
| Bone marrow | 41 (100) |
| Donor,* n (%) | |
| Histocompatible unrelated donor | 26 (68) |
| 5 of 6 unrelated donor | 8 (20) |
| 5 of 6 matched family member | 5 (12) |
| Diagnosis | |
| CML, n (%) | 12 (29) |
| Stable phase | 8 |
| Accelerated phase or second stable phase | 2 |
| Blast crisis | 2 |
| ALL, n (%) | 9 (22) |
| First remission | 4† |
| Second remission | 4 |
| Resistant relapse | 1 |
| AML, n (%) | 10 (24) |
| Second remission | 1 |
| Resistant relapse | 8 |
| Untreated relapse | 1 |
| Myelodysplasia, n (%) | 7 (17) |
| Non-Hodgkin lymphoma, n (%) | 2 (5) |
CML indicates chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.
Mismatch locus: Unrelated donor disparity: HLA-A (n = 4), HLA-B (n = 3), HLA-DR (n = 1). Related donor disparity: HLA-A (n = 4), HLA-DR (n = 1). Donor-recipient disparity at HLA-C (n = 8), HLA-DRB3 (n = 1), and HLA-DQ (n = 3) were not considered to be mismatched. Two unrelated donors were mismatched at both HLA-B and HLA-C, and one was mismatched at HLA-A and HLA-C. These were counted as single antigen mismatches.
All 4 patients had high-risk cytogenetics or clinical features.